INDUSTRY BRIEF: Healthcare stocks under pressure as national drug list expands
Many Hong Kong-listed drugmakers on Monday announced their products that were included in the 2025 edition of China’s National Reimbursement Drug List (NRDL), which was unveiled this week. The updated…
A McDonald’s Valuation Downsize, and New Medical Plan Additions
The value of McDonald's China operation has plunged by more than half in the last year. And 91 companies got their drugs added to China's national health plan By Doug…
RELATED ARTICLES
-
Zai Lab under pressure over clinical results and rival drugs
9688.HKZLAB.US -
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
